Shield Therapeutics takes bold approach in the US

0
50
  • Shield Therapeutics names Jose A. Menoyo as chief medical officer
  • Shield Therapeutics’ present drive for US launch success of iron deficiency product Accrufer
Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC

Follow

View company profile

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru(R)/Accrufer(R), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.

27 Sep 2021

(, ) said Jose A. Menoyo, M.D., is joining its senior executive team as vice president and chief medical officer with immediate effect, in a move that is expected to help the launch of its iron deficiency treatment Accrufer in the US.

Dr. Menoyo most recently served as head of US Medical Affairs at rare disease specialist Alexion Pharmaceuticals, Inc., which was acquired by () in July this year. In this role, Menoyo led the Medical Affairs and Health Outcomes and Research teams that supported several launches in the rare disease area.

Prior to joining Alexion, Dr. Menoyo was the senior vice president of Clinical Development and Medical Affairs for (), which was also eventually acquired by AstraZeneca.

He has also held leadership roles at Amgen, () and Sanofi.

Read more

17 Aug 2021

(, ) () said in its half-year results that the focus in the second half will be on the roll-out of its iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

Read more

12 Aug 2021

(, ) shares surged on Thursday as it said it has secured a licence agreement in South Korea for its Accrufer iron deficiency therapy.

Under the deal with Korea Pharma Co Ltd, the company said it will receive an upfront payment of GBP0.5mln and is also eligible to receive a further GBP1.5mln upon the first commercial sale of Accrufer in Korea.

Read more

17 Aug 2021

(, ) () new CEO Greg Madison talks to Proactive London about his strategy for the company and focus on driving the iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

During the second quarter of 2021, the company built up a sales force and started to contact key prescribers. Due to the ongoing impact of the COVID pandemic and the emergence of the delta variant in the US, face-to-face contact with clinicians has been limited in the initial phase of launch but discussions are taking place with payers regarding formulary placement of Accrufer and will continue over the next several months.

25 Aug 2021

Shield’s investment proposition is very simple: it hinges on its US success in commercialising Accrufer (US brand) to treat iron deficient anaemia using its own 30-person salesforce and a striking ad campaign. Shield owns the product, takes all the profit but, most importantly, controls the process.

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics’ on cusp of US market expansion with focus on…

Shield Therapeutics PLC (LSE:STX, FRA:1JS)’s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer.

This treatment is for iron deficiency or anaemia and as…

on 25/8/21

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here